Open AccessImproved Renal Function During Chronic Lisinopril Treatment in Moderate to Severe Primary Hypertension
Author(s) -
Dupont Ag,
Patricia Van der Niepen,
A Volckaert,
Michel Ingels,
Bossuyt Am,
Jonckheer Mh,
Six Ro
Publication year - 1987
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-198706107-00032
Subject(s) - lisinopril , renal function , medicine , blood pressure , hemodynamics , placebo , renal blood flow , urology , heart rate , cardiology , nifedipine , angiotensin converting enzyme , pathology , alternative medicine , calcium
The effect of the converting enzyme inhibitor lisinopril on renal and cardiac hemodynamics was studied in patients with moderate to severe primary hypertension, in a multicenter, double-blind, randomized clinical trial comparing the antihypertensive effect of lisinopril (LIS) and nifedipine (NIF). After a 2 week placebo run-in period, 15 patients were randomized in a 2:1 ratio to receive either LIS (20-80 mg q.d., n = 10) or NIF (20-40 mg b.i.d., n = 5). LIS significantly reduced blood pressure (BP) without changing heart rate or cardiac output. LIS significantly increased renal blood flow; glomerular filtration rate (GFR) was not changed. It can be concluded that LIS is an effective antihypertensive agent with a favorable renal hemodynamic profile.